Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Summary · Treatments & Research

Recent developments regarding the treatment and research of multiple myeloma indicate promising advances. [USA] A new bispecific antibody targeting BCMA is being tested in patients with relapsed multiple myeloma, while [UK] the inhibition of the NFIL3-MYC axis is emerging as a strategy to overcome therapeutic resistance. [Unidentified Country] New therapies, including CAR-T therapies and antibody combinations, are being approved, and FDA data analysis suggests the potential of Teclistamab with Daratumumab.

Made by MielomaAI On November 17, 2026, at 09:45, based on recent news. May contain errors. View news →

Compare treatments

This page brings together the numbers from the treatment sheets to put them side by side. Note: each trial had different patients (some early in the disease, others after many treatments). The fairest comparison is always within the same trial, between the new treatment and the control. The choice of treatment is always made with your haematology team.

Median progression-free time

Time after which half of the patients still did not have their disease getting worse. Striped bar: not yet reached (more than half were still progression-free when the study was published). Dark bars: treatment studied; light bars: control arm.

First line (newly diagnosed patients)

VRd + transplant · DETERMINATION67,5 meses
D-VRd (with daratumumab), no transplant · CEPHEUSainda não atingida
VRd, no transplant (control arm) · CEPHEUS52,6 meses
VRd without immediate transplant · DETERMINATION46,2 meses

Relapse (previously treated patients)

Cilta-cel (CAR-T), from the 2nd line · CARTITUDE-4ainda não atingida
BVd (belantamab) · DREAMM-736,6 meses
Cilta-cel (CAR-T), after many treatments · CARTITUDE-134,9 meses
BPd (belantamab) · DREAMM-832,6 meses
MeziKd (mezigdomide) · SUCCESSOR-218 meses
Ide-cel (CAR-T) · KarMMa-313,8 meses
PVd (control arm) · DREAMM-812,5 meses
Standard treatment (control arm) · CARTITUDE-411,8 meses
Kd (control arm) · SUCCESSOR-28,3 meses
Standard treatment (control arm) · KarMMa-34,4 meses

Sources: DETERMINATION — ASCO Post ↗ · CEPHEUS — CancerNetwork ↗ · CARTITUDE-4 — CancerNetwork ↗ · DREAMM-7 — Haematologica ↗ · CARTITUDE-1 — CancerNetwork ↗ · DREAMM-8 — CancerNetwork ↗ · SUCCESSOR-2 — IMF ↗ · KarMMa-3 — Blood ↗

How much extra time, within the same trial

Difference between the median progression-free time of the treatment studied and that of the control arm, in the same trial.

DETERMINATION: transplant straight away, instead of later+21,3 meses (67,5 contra 46,2)
DREAMM-8: BPd instead of PVd+20,1 meses (32,6 contra 12,5)
SUCCESSOR-2: MeziKd instead of Kd+9,7 meses (18 contra 8,3)
KarMMa-3: ide-cel instead of standard+9,4 meses (13,8 contra 4,4)

In CARTITUDE-4 (cilta-cel) and CEPHEUS (D-VRd) the new treatment has not yet reached the median, so the gain cannot be calculated yet (in CARTITUDE-4, the control arm was at 11.8 months).

Price and benefit

Sorted by known efficacy (median progression-free time). Prices are US list prices, before discounts, converted to euros; in Portugal prices are confidential and, in the SNS, the patient does not pay for treatment.

TreatmentMedian progression-free timeList price (USA, in euros)Cost per progression-free month*How it is given
VRd (bortezomib, lenalidomida, dexametasona)46.2 months
DETERMINATION, no immediate transplant
166.298 € por ano13.858 € (enquanto dura)Continuous cycles
Cilta-cel (Carvykti) — CAR-T34.9 months
CARTITUDE-1 (after many treatments); in CARTITUDE-4 not yet reached
502.452 € (uma vez)14.397 €A single infusion
Ide-cel (Abecma) — CAR-T13.8 months
KarMMa-3
478.024 € (uma vez)34.639 €A single infusion
DRd (daratumumab, lenalidomida, dexametasona)—
—
345.691 € por ano28.808 € (enquanto dura)Continuous, until it stops working
Teclistamab (Tecvayli) — biespecífico—
—
35.740 € por mês35.740 € (enquanto dura)Weekly injection, then every two weeks
Elranatamab (Elrexfio) — biespecífico—
MagnetisMM-32: not yet reached
37.550 € por mês37.550 € (enquanto dura)Weekly injection, then every two weeks
Talquetamab (Talvey) — biespecífico—
—
40.717 € por mês40.717 € (enquanto dura)Weekly or two-weekly injection

* For one-off treatments (CAR-T), the price divided by the median progression-free time; for continuous ones, the cost of each month of treatment. It is a simple calculation, only to give an idea: it does not include hospital stays, tests, transport or treatment of side effects, and the trial patients were different. In Portugal, an IPO Porto study calculated a median total cost of 355.165 € per patient treated with CAR-T (including hospital). Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. More details in the tab Costs.

Treatment burden for the patient

There is no single measure of how hard each treatment is. We show what is known objectively: how it is given, time in hospital, how long it lasts and the most frequent severe effect (grade 3 or higher) in the trials.

Most frequent severe effect (% of patients)

CAR-T (cilta-cel) · Severe infections27%
Bispecifics (teclistamab) · Severe infections44,8%
Bispecifics (elranatamab) · Severe infections27,5%
Belantamab (BVd) · Severe corneal and vision changes77%
D-VRd (first line) · Severe infections40,1%
TreatmentHow it is givenTime in hospitalDuration
CAR-T (cilta-cel)Blood collection, manufacturing, one infusionCollection of 4 to 6 hours; infusion and daily monitoring in the first 2 weeks; stay near the hospital for about 4 weeksOnce
Bispecifics (teclistamab)Injection under the skinFirst doses with close monitoring; then a few minutes at the day hospitalContinuous, as long as it works
Bispecifics (elranatamab)Injection under the skinLike teclistamabContinuous, as long as it works
Belantamab (BVd)Infusion into a veinAbout 30 minutes, every 3 weeks, and eye appointmentsContinuous
D-VRd (first line)Injections and tabletsDaratumumab: 3 to 5 minutes; bortezomib: a few minutes; the rest at homeMonths of induction and then maintenance
Autologous transplantHigh-dose chemotherapy and return of the cellsA hospital stay of about 2 to 3 weeksOnce (sometimes twice)

Quality of life: in CARTITUDE-4, patients treated with cilta-cel reported clinically meaningful improvements in quality of life compared with standard treatment (Legend Biotech ↗). A one-off treatment (CAR-T, transplant) is harder at first but then leaves a period without treatment; continuous ones are lighter each time but mean regular hospital visits. Approximate times, taken from each treatment's film; they may vary from hospital to hospital. The side effects of each treatment are in the treatment sheets and in the sub-tab Trials.

Latest news on treatments

All news → · Summaries created by MielomaAI; expand the article to read the original.